Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ORG 2766
- Development stage
- Unknown
- Lead developer
- AkzoNobel
- Modality
- Small Molecules, Peptides
- Administration
- Oral
01
Overview
ORG 2766 is a synthetic analog of adrenocorticotropic hormone (ACTH) consisting of amino acids 4-9 of the ACTH sequence[1][2][3][4][6]. It acts as a **Melanocortin receptor 2 agonist (ACTH receptor agonist)** and exhibits neurotrophic effects, influencing memory, attention, and behavioral processes[1][6]. Developed primarily for neuropsychiatric and neurodegenerative disorders, it showed potential to reduce social withdrawal and stereotypic behaviors in children with autism, but clinical evidence was mixed[2][3][4]. Primary indications explored were **dementia, diabetic neuropathies, amnesia,** and **autistic disorder**[1][2][3][4].
- Other names
- ACTH (4-9) analogadrenocorticotropic hormone (4-9) analog
02
Targets
MCR (Melanocortin receptor family)MC2R (Adrenocorticotropic Hormone Receptor)
Beyond the preview
Go deeper on ORG 2766.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ORG 2766.